Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: a phase II study

Απλή σελίδα τεκμηρίου
dc.contributor.authorKosmidis, P. A.en
dc.contributor.authorMylonakis, N.en
dc.contributor.authorFountzilas, G.en
dc.contributor.authorSamantas, E.en
dc.contributor.authorAthanasiadis, A.en
dc.contributor.authorAndreopoulou, E.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorSkarlos, D.en
dc.date.accessioned2015-11-24T19:00:11Z
dc.date.available2015-11-24T19:00:11Z
dc.identifier.issn0923-7534-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19494
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*therapeutic useen
dc.subjectCarboplatin/administration & dosage/adverse effectsen
dc.subjectCarcinoma, Non-Small-Cell Lung/*drug therapyen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectLung Neoplasms/*drug therapyen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPaclitaxel/administration & dosage/adverse effectsen
dc.titlePaclitaxel and carboplatin in inoperable non-small-cell lung cancer: a phase II studyen
heal.abstractBACKGROUND: Based on the high activity of single-agent paclitaxel and the superior one-year survival rates of patients with non-small-cell lung cancer (NSCLC) treated with carboplatin, a phase II trial was initiated using both agents in patients with inoperable stages III and IV disease to investigate the efficacy and toxicity of the combination. PATIENTS AND METHODS: Since July 1995, 60 patients fulfilling all eligibility criteria entered this study. All patients received paclitaxel 175 mg/m2 as a three-hour infusion, and carboplatin dosed to an area under the concentration-time curve of seven, every three weeks. No granulocyte colony-stimulating factor was given. Of the 56 male and four female patients, the median age was 57 years (range 29 to 75 years) and the median Eastern Co-Operative Oncology Group performance status was one. Most of the patients had stage IV (34) adenocarcinoma (31) with low differentiation (28). The median number of chemotherapy cycles was three, with a range of one to eight. RESULTS: Of 55 evaluable patients, 15 (27.3%) achieved partial responses, 15 (27.3%) had stable disease, and 25 (45.4%) had progressive disease. The median survival was 8.95 months and 21.6% of the patients survived more than one year. Grade 2/3 nonhematologic toxicity included alopecia (59%), neurotoxicity (3%), and myalgia/arthralgia (10%). Grade 2/3 neutropenia occurred in 14% of patients, whereas grade 3/4 thrombocytopenia was seen in only 4%. One patient died of complications of a severe allergic reaction. CONCLUSION: Combination treatment using paclitaxel and carboplatin is active and well tolerated in patients with inoperable non-small-cell lung cancer. The dose-response relationship to paclitaxel and results of comparison with other platinum-based regimens remain to be determined.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/9296226-
heal.identifier.secondaryhttp://annonc.oxfordjournals.org/content/8/7/697.full.pdf-
heal.journalNameAnn Oncolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1997-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ